Advanced search
Publication Cover
Cell Cycle Volume 16, 2017 - Issue 19
Submit an article Journal homepage
2,997
Views
42
CrossRef citations to date
0
Altmetric
Reports

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212

Jessica WagnerLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAORCID Iconhttp://orcid.org/0000-0003-2587-3310
ORCID Icon,
Christina Leah KlineLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAORCID Iconhttp://orcid.org/0000-0001-7764-0119
ORCID Icon,
Marie D. RalffLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAORCID Iconhttp://orcid.org/0000-0003-2113-0974
ORCID Icon,
Avital LevLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAORCID Iconhttp://orcid.org/0000-0002-2127-7338
ORCID Icon,
Amriti LullaLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAORCID Iconhttp://orcid.org/0000-0002-7085-5755
ORCID Icon,
Lanlan ZhouLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAORCID Iconhttp://orcid.org/0000-0001-9471-9099
ORCID Icon,
Gary L. OlsonProvid Pharmaceuticals, Monmouth Junction, NJ, USA
,
Bhaskara Rao NallaganchuProvid Pharmaceuticals, Monmouth Junction, NJ, USA
,
Cyril H. BenesMassachusettes General Hospital, Boston, MA, USA
,
Joshua E. AllenOncoceutics, Inc., Philadelphia, PA, USA
,
Varun V. PrabhuOncoceutics, Inc., Philadelphia, PA, USA
,
Martin StogniewOncoceutics, Inc., Philadelphia, PA, USA
,
Wolfgang OsterOncoceutics, Inc., Philadelphia, PA, USA
&
Wafik S. El-DeiryLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USACorrespondence[email protected]
 show all
Pages 1790-1799 | Received 17 Apr 2017, Accepted 24 Apr 2017, Published online: 22 Sep 2017

References

  • Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 2016; 9(415):ra17; PMID:26884599; https://doi.org/10.1126/scisignal.aac4380
  • Kline CL, Van den Heuvel AP, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases. Sci Signal 2016; 9(415):ra18; PMID:26884600; https://doi.org/10.1126/scisignal.aac4374
  • Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013; 5(171):171ra17; PMID:23390247; https://doi.org/10.1126/scitranslmed.3004828
  • Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008; 19(3-4):325-31; PMID:18495520; https://doi.org/10.1016/j.cytogfr.2008.04.001
  • Pan G, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276(5309):111-3; PMID:9082980; https://doi.org/10.1126/science.276.5309.111
  • Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/TRAIL-dependent manner. Cancer Res 2015; 75(7):1423-32; PMID:25712124; https://doi.org/10.1158/0008-5472.CAN-13-3451
  • Zhang Q, Wang H, Ran L, Zhang Z, Jiang R. The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent. Biochem Biophys Res Commun 2016; 476(4):260-6; PMID:27233611; https://doi.org/10.1016/j.bbrc.2016.05.106
  • Allen J, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 2016; 7(45):74380-92
  • Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez-Rodriguez L, Aisner J, et al. First-in-human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clin Cancer Res 2017; 23(15): 4163-69; PMID:28331050
  • Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget 2014; 5(24):12728-37; PMID:25587031; https://doi.org/10.18632/oncotarget.2890
  • Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7(1):94-100; PMID:11135622; https://doi.org/10.1038/83416
  • Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, Schütz G, Greiner EF, Kemp CJ, Walczak H. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008; 118(1):100-10; PMID:18079967; https://doi.org/10.1172/JCI33061
  • Eisenberg MC, Kim Y, Li R, Ackerman WE, Kniss DA, Friedman A. Mechanistic modeling of the effects of myoferlin on tumor cell invasion. Proc Natl Acad Sci U S A 2011; 108(50):20078-83; PMID:22135466; https://doi.org/10.1073/pnas.1116327108
  • Yuan M, Breitkopf SB, Yang X, Asara JM. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc 2012; 7(5):872-81; PMID:22498707; https://doi.org/10.1038/nprot.2012.024
  • Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483(7391):570-5; PMID:22460902; https://doi.org/10.1038/nature11005
  • Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013; 41(Database issue):D955-61; PMID:23180760; https://doi.org/10.1093/nar/gks1111

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.